Huntington's Disease Contract Update

IXICO plc, the data analytics company delivering insights in neuroscience, announces a further update to the Huntington's disease Phase III contract.

As previously announced on 23 March 2021, the client decided to stop dosing participants in its Phase III trial in Huntington's disease following a pre-planned review of the data.  In April 2021, it was announced that the client had agreed a revised protocol for these trials which provided for IXICO's safety and data analysis services to continue to be utilised to support further understanding of the trialled drug candidate data in an open-label extension.

The client has now confirmed that it will close its open-label extension study in Huntington's disease in May 2022 which is expected to result in a reduction in 2022 revenues of £0.3 million. This means that, including the loss of expected revenues for the remaining 3-year period of the contract, the Company now has an order book totalling £12.6 million.

The Company continues to have a strong pipeline of opportunities including with this client which is now in the early stages of designing a new Phase II clinical trial to explore different doses of the investigative drug in its ongoing efforts to identify a disease modifying treatment for Huntingdon's disease.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)

For further information please contact:

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 

 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

 

Michael F Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or IXICO@walbrookpr.com

Paul McManus / Lianne Cawthorne /

Mob: 07980 541 893 / 07584 391 303 /

Alice Woodings

07407 804 654

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com


Date: 20/01/2022